journal of men's health
Volume 5 , Pages S2-S6 , September 2008

Introduction: Testosterone and the metabolic syndrome

  • Louis Gooren, MD, PhD

      Affiliations

    • Endocrinology, Vrije Universiteit medical center, Amsterdam, the Netherlands
    • Corresponding Author InformationCorresponding author.
    • ,
  • Siegfried Meryn, MD

      Affiliations

    • Institute for Medical Education, University of Vienna, Vienna, Austria
    • ,
  • Ridwan Shabsigh, MD

      Affiliations

    • Division of Urology, Maimonides Medical Center, Columbia University, Brooklyn, NY, USA

References 

  1. Morgentaler A. Testosterone and Prostate Cancer: An Historical Perspective on a Modern Myth. Eur Urol. 2006;50(5):935–939
  2. Nieschlag E. Testosterone treatment comes of age: new options for hypogonadal men. Clin Endocrinol (Oxf). 2006;65(3):275–281
  3. Liu PY, Death AK, Handelsman DJ. Androgens and cardiovascular disease. Endocr Rev. 2003;24(3):313–340
  4. Wu FC, von Eckardstein A. Androgens and coronary artery disease. Endocr Rev. 2003;24(2):183–217
  5. Nieschlag E, Nieschlag S, et al. Lifespan and testosterone. Nature. 1993;366(6452):215
  6. Tibblin G, Adlerberth A, et al. The pituitary-gonadal axis and health in elderly men: a study of men born in 1913. Diabetes. 1996;45(11):1605–1609
  7. Laaksonen DE, Niskanen L, et al. Testosterone and sex hormone-binding globulin predict the metabolic syndrome and diabetes in middle-aged men. Diabetes Care. 2004;27(5):1036–1041
  8. Muller M, Grobbee DE, et al. Endogenous sex hormones and metabolic syndrome in aging men. J Clin Endocrinol Metab. 2005;90(5):2618–2623
  9. Selvin E, Feinleib M, et al. Androgens and diabetes in men: results from the Third National Health and Nutrition Examination Survey (NHANES III). Diabetes Care. 2007;30(2):234–238
  10. Kapoor D, Malkin CJ, et al. Androgens, insulin resistance and vascular disease in men. Clin Endocrinol (Oxf). 2005;63(3):239–250
  11. Makhsida N, Shah J, et al. Hypogonadism and metabolic syndrome: implications for testosterone therapy. J Urol. 2005;174(3):827–834
  12. Rodriguez A, Muller DC, et al. Aging, Androgens, and the Metabolic Syndrome in a Longitudinal Study of Aging. J Clin Endocrinol Metab. 2007;92(9):3568–3572
  13. Yesilova Z, Oktenli C, et al. Evaluation of insulin sensitivity in patients with Klinefelter's syndrome: a hyperinsulinemic euglycemic clamp study. Endocrine. 2005;27(1):11–15
  14. Pitteloud N, Mootha VK, et al. Relationship between testosterone levels, insulin sensitivity, and mitochondrial function in men. Diabetes Care. 2005;28(7):1636–1642
  15. Yialamas MA, Dwyer AA, et al. Acute Sex Steroid Withdrawal Reduces Insulin Sensitivity in Healthy Men with Idiopathic Hypogonadotropic Hypogonadism. J Clin Endocrinol Metab. 2007;92(11):4254–4259
  16. Gould DC, Kirby RS, et al. Hypoandrogen-metabolic syndrome: a potentially common and underdiagnosed condition in men. Int J Clin Pract. 2007;61(2):341–344
  17. Rohrmann S, Smit E, et al. Association between markers of the metabolic syndrome and lower urinary tract symptoms in the Third National Health and Nutrition Examination Survey (NHANES III). Int J Obes (Lond). 2005;29(3):310–316
  18. Kasturi S, Russell S, et al. Metabolic syndrome and lower urinary tract symptoms secondary to benign prostatic hyperplasia. Curr Urol Rep. 2006;7(4):288–292
  19. McVary K. Lower urinary tract symptoms and sexual dysfunction: epidemiology and pathophysiology. BJU Int. 2006;97(Suppl 2):23–28discussion 44-5
  20. Rosen RC. Update on the relationship between sexual dysfunction and lower urinary tract symptoms/benign prostatic hyperplasia. Curr Opin Urol. 2006;16(1):11–19
  21. Yassin ASF. Erectile dysfunction, metabolic syndrome, hypogonadism are intertwined. J Urol. 2007;177:288
  22. Baillargeon J, Rose DP. Obesity, adipokines, and prostate cancer (review). Int J Oncol. 2006;28(3):737–745
  23. Tande AJ, Platz EA, et al. The metabolic syndrome is associated with reduced risk of prostate cancer. Am J Epidemiol. 2006;164(11):1094–1102
  24. Cowey S, Hardy RW. The metabolic syndrome: A high-risk state for cancer?. Am J Pathol. 2006;169(5):1505–1522
  25. Kylin E. Studien.Hypertonie-Hyperglykemie-Hyperurikamiesyndrome. Zentralblatt fur inner Medizin 1923; 44.
  26. Vague J. La differenciation sexuelle, facteur determinant des form de l’obesite Presse. Med. 1947;30
  27. Björntorp P. Abdominal obesity and the metabolic syndrome. Ann Med. 1992;24(6):465–468
  28. Björntorp P. Visceral obesity: a “civilization syndrome”. Obes Res. 1993;1(3):206–222
  29. Roemmich JN, Clark PA, et al. Alterations in growth and body composition during puberty: III. Influence of maturation, gender, body composition, fat distribution, aerobic fitness, and energy expenditure on nocturnal growth hormone release. J Clin Endocrinol Metab. 1998;83(5):1440–1447
  30. Onat A, Hergenc G, et al. Serum sex hormone-binding globulin, a determinant of cardiometabolic disorders independent of abdominal obesity and insulin resistance in elderly men and women. Metabolism. 2007;56(10):1356–1362
  31. Katznelson L, Rosenthal DI, et al. Using quantitative CT to assess adipose distribution in adult men with acquired hypogonadism. AJR Am J Roentgenol. 1998;170(2):423–427
  32. Smith MR, Finkelstein JS, et al. Changes in body composition during androgen deprivation therapy for prostate cancer. J Clin Endocrinol Metab. 2002;87(2):599–603
  33. Smith RM, Nathan LH. Insulin sensitivity during combined androgen blockade for prostate cancer. J Clin Endocrinol Metab. 2006;91:1305–1308
  34. Zmuda JM, Cauley JA, et al. Longitudinal relation between endogenous testosterone and cardiovascular disease risk factors in middle-aged men. A 13-year follow-up of former Multiple Risk Factor Intervention Trial participants. Am J Epidemiol. 1997;146(8):609–617
  35. Tsai EC, Boyko EJ, et al. Low serum testosterone level as a predictor of increased visceral fat in Japanese-American men. Int J Obes Relat Metab Disord. 2000;24(4):485–491
  36. Rosmond R, Wallerius S, et al. A 5-year follow-up study of disease incidence in men with an abnormal hormone pattern. J Intern Med. 2003;254(4):386–390
  37. Kaufman JM, Vermeulen A. The decline of androgen levels in elderly men and its clinical and therapeutic implications. Endocr Rev. 2005;26(6):833–876
  38. Norman RJ, Dewailly D, et al. Polycystic ovary syndrome. Lancet. 2007;370(9588):685–697
  39. Tchernof A, Poehlman ET. Effects of the menopause transition on body fatness and body fat distribution. Obes Res. 1998;6(3):246–254

PII: S1875-6867(08)00069-9

doi: 10.1016/j.jomh.2008.03.008

journal of men's health
Volume 5 , Pages S2-S6 , September 2008

Article Tools